Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study.
Frangos S, Iakovou IP, Marlowe RJ, Eftychiou N, Patsali L, Vanezi A, Savva A, Mpalaris V, Giannoula EI. Frangos S, et al. Among authors: vanezi a. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2045-55. doi: 10.1007/s00259-015-3124-4. Epub 2015 Aug 1. Eur J Nucl Med Mol Imaging. 2015. PMID: 26231351
Erratum to: Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study.
Frangos S, Iakovou IP, Marlowe RJ, Eftychiou N, Patsali L, Vanezi A, Savva A, Mpalaris V, Giannoula EI. Frangos S, et al. Among authors: vanezi a. Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):206-207. doi: 10.1007/s00259-015-3238-8. Eur J Nucl Med Mol Imaging. 2016. PMID: 26526594 No abstract available.
Acknowledging gray areas: 2015 vs. 2009 American Thyroid Association differentiated thyroid cancer guidelines on ablating putatively low-intermediate-risk patients.
Frangos S, Iakovou IP, Marlowe RJ, Eftychiou N, Patsali L, Vanezi A, Savva A, Mpalaris V, Giannoula EI. Frangos S, et al. Among authors: vanezi a. Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):185-189. doi: 10.1007/s00259-016-3495-1. Epub 2016 Aug 25. Eur J Nucl Med Mol Imaging. 2017. PMID: 27557846 Clinical Trial.